Predictors of lethal outcome in patients with tuberculosis, resistance to rifampicin, and HIV infection

• Published in: Tuberkulëz i bolezni lëgkikh Vol. 98; no. 5; pp. 44 - 50
• Main Authors: Saenko, S. S., Sterlikov, S. A., Saenko, G. I.
• Format: Journal Article
• Language: English
• Published: New Terra Publishing House 03-06-2020
• Subjects: сочетание туберкулез и вич-инфекция; туберкулез с устойчивостью к рифампицину; факторы риска летального исхода
• ISSN: 2075-1230; 2542-1506
• DOI: 10.21292/2075-1230-2020-98-5-44-50

The objective: to identify and rank the predictors of lethal outcome in patients with tuberculosis resistance to at least rifampicin and concurrent HIV infection (TB-R/HIV).Subjects and methods. 130 cases TB-R/HIV notified in Rostov Region in 2017-2018 were included in an observational retrospective cohort study. Two cohorts were formed: cohort A consisted of 31 patients with a documented fatal outcome within 12 months after registration for treatment, cohort B included 99 patients didn't die at least during the first year after registration for treatment. At the first stage of the study, the statistical significance of differences of certain signs in patients of cohorts A and B was determined. The signs with confirmed statistical significance of differences were included in the second stage of the study, during which their sensitivity as predictors of lethal outcome was determined. For this, automated artificial neural networks were used.Results. The following can be used as predictors of lethal outcome for TB-R/HIV patients (in decreasing order of significance): homelessness (people who have no place of residence), addiction to alcohol or drugs, interruption of anti-TB chemotherapy in the past, low body mass index, low hemoglobin level, including anemia (but not severe), low level of CD4 T-lymphocytes (the prognosis is especially unfavorable with less than 100 cells/μl). The level of total protein may also be a potential predictor, however, the selection criteria for this indicator require further clarification.